Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy
Latest Information Update: 28 Aug 2023
At a glance
- Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Nasopharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 28 Aug 2023 New trial record